In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...

Fifty percent of T2DM patients also have NAFLD, confirmed via ultrasound, with elevated liver enzymes and altered lipid profiles. NAFLD and T2DM are key components of metabolic syndrome, sharing risk ...